CRISPR THERAPEUTICS
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CRISPR THERAPEUTICS
Industry:
Biopharma Biotechnology Genetics Medical
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.crisprtx.com
Total Employee:
101+
Status:
Active
Contact:
141794589327
Email Addresses:
[email protected]
Total Funding:
127 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Nginx Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - CRISPR Therapeutics
Wellington Capital Management
Wellington Capital Management investment in Series B - CRISPR Therapeutics
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - CRISPR Therapeutics
Clough Capital Partners
Clough Capital Partners investment in Series B - CRISPR Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - CRISPR Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - CRISPR Therapeutics
Versant Ventures
Versant Ventures investment in Series B - CRISPR Therapeutics
SR One
SR One investment in Series B - CRISPR Therapeutics
Abingworth
Abingworth investment in Series B - CRISPR Therapeutics
Vertex Pharmaceuticals
Vertex Pharmaceuticals investment in Series B - CRISPR Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-17 | On a Roll, CRISPR TX Taps Amgen Veteran P.K. Morrow as New CMO |
| 2021-10-14 | CRISPR Therapeutics Announces Transition of Chief Financial Officer |
Official Site Inspections
http://www.crisprtx.com Semrush global rank: 315.99 K Semrush visits lastest month: 197.21 K
- Host name: 64.62.152.250
- IP address: 64.62.152.250
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CRISPR Therapeutics"
Who We Are | CRISPR Therapeutics
At CRISPR Therapeutics, our aim is to find cures for people suffering from serious diseases through transformative gene-based medicines. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy.See details»
CRISPR Therapeutics - Wikipedia
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, …See details»
CRISPR Therapeutics - LinkedIn
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. …See details»
CRISPR Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 141794589327 CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene …See details»
Corporate Responsibility - CRISPR Therapeutics
CRISPR Therapeutics is focused on the development of transformative gene-based medicines for serious diseases. This mission defines our company, unites our teams, and inspires our work.See details»
CRISPR Therapeutics Company Profile - Craft
Oct 29, 2024 CRISPR Therapeutics has 5 employees across 4 locations and $371.21 m in annual revenue in FY 2023. See insights on CRISPR Therapeutics including office locations, …See details»
CRISPR Therapeutics Strengthens Executive Leadership Team with …
May 23, 2024 -Naimish Patel, M.D., appointed to Chief Medical Officer--Julianne Bruno, M.B.A., promoted to Chief Operating Officer-ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE …See details»
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
Jan 8, 2024 ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
CRISPR Therapeutics Announces the Appointment of Philippe …
Feb 1, 2021 ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
CRISPR Therapeutics Provides Business Update… | CRISPR …
Mar 31, 2024 [email protected]. Media Contact: Rachel Eides +1-617-315-4493 [email protected]. CRISPR Therapeutics AG Condensed Consolidated Statements …See details»
CRISPR Therapeutics to Participate in Upcoming Investor …
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
CRISPR Therapeutics Announces Transition of Chief Financial Officer
Oct 14, 2021 ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
CRISPR-X | CRISPR Therapeutics
We have a dedicated team called CRISPR-X that focuses on innovative research to develop next-generation editing and delivery modalities, such as all-RNA gene correction, whole gene …See details»
Home | CRISPR
First-ever approved crispr-based therapy. CASGEVY™ (Exagamglogene Autotemcel), a CRISPR/Cas9 Gene-Edited Therapy Arising Out of Our Collaboration with Vertex …See details»
Press Release - CRISPR Therapeutics
Feb 21, 2024 Vertex reported progress on CASGEVY launch in the U.S. with the activation of 12 authorized treatment centers (ATCs) in the U.S. and the signing of an agreement with …See details»
CRISPR Therapeutics Announces Transition of… | CRISPR …
Oct 14, 2021 CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 …See details»
CRISPR Therapeutics Provides Business Update and Reports Third …
Nov 3, 2021 [email protected] . Media Contact: Rachel Eides +1-617-315-4493 [email protected] . CRISPR Therapeutics AG Condensed Consolidated Statements …See details»
CRISPR Therapeutics Announces Updates to… | CRISPR Therapeutics
Dec 4, 2023 CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 …See details»
Press Release - CRISPR Therapeutics
Nov 22, 2021 ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»